Envestnet Portfolio Solutions Inc. Has $1.11 Million Stake in Natera, Inc. (NASDAQ:NTRA)

Envestnet Portfolio Solutions Inc. reduced its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 24.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,838 shares of the medical research company's stock after selling 2,578 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Natera were worth $1,108,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of NTRA. Vanguard Group Inc. boosted its position in shares of Natera by 7.7% in the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock valued at $1,949,697,000 after purchasing an additional 879,463 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after purchasing an additional 3,871,862 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Natera by 43.7% in the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares during the period. Wellington Management Group LLP boosted its position in shares of Natera by 15.7% in the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock valued at $512,898,000 after purchasing an additional 439,778 shares during the period. Finally, Geode Capital Management LLC boosted its position in shares of Natera by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company's stock valued at $355,809,000 after purchasing an additional 142,201 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Price Performance

Shares of NTRA stock traded down $0.21 during trading on Friday, reaching $167.96. The company had a trading volume of 3,082,525 shares, compared to its average volume of 1,422,762. The firm's 50 day simple moving average is $158.92 and its two-hundred day simple moving average is $158.53. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00. The company has a market capitalization of $22.93 billion, a PE ratio of -114.26 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. The company had revenue of $501.83 million for the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company's revenue for the quarter was up 36.5% on a year-over-year basis. During the same period in the previous year, the business posted ($0.56) EPS. Analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on NTRA shares. Barclays increased their price target on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research report on Friday, May 9th. Wall Street Zen lowered Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. BTIG Research restated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Piper Sandler raised their price objective on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. Finally, UBS Group raised their price objective on Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $184.63.

Insider Transactions at Natera

In related news, CFO Michael Burkes Brophy sold 495 shares of the business's stock in a transaction on Wednesday, April 23rd. The stock was sold at an average price of $150.74, for a total value of $74,616.30. Following the sale, the chief financial officer now owns 76,312 shares of the company's stock, valued at $11,503,270.88. The trade was a 0.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John Fesko sold 343 shares of the business's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $145.55, for a total value of $49,923.65. Following the completion of the sale, the insider now directly owns 156,946 shares in the company, valued at approximately $22,843,490.30. This represents a 0.22% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 59,755 shares of company stock valued at $8,898,589. 7.60% of the stock is owned by corporate insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.